# Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma

> **NCT01735747** · PHASE2 · UNKNOWN · sponsor: **Rongjie Tao** · enrollment: 16 (estimated)

## Conditions studied

- Central Nervous System Tumors

## Interventions

- **RADIATION:** Radiotherapy
- **DRUG:** nedaplatin
- **DRUG:** vincristine
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT01735747
- **Lead sponsor:** Rongjie Tao
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-06
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2013-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01735747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01735747, "Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01735747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*